Diaceutics (LSE:DXRX) EBIT: £0.36 Mil (TTM As of Dec. 2025)


LSE:DXRX Diaceutics PLC LSE:DXRX
92 GF Score
Price £1.45
GF Value £1.91
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Diaceutics EBIT?

Diaceutics LSE:DXRX 92 EBIT is £0.36 Mil as of Dec. 2025. GuruFocus rates LSE:DXRX with a GF Score™ of 92/100 and a GF Value™ of £1.91 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Diaceutics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was £3.34 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was £0.36 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Diaceutics's annualized ROC % for the quarter that ended in Dec. 2025 was 13.30%. Diaceutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 131.06%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Diaceutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.31%.

Diaceutics  (LSE:DXRX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Diaceutics's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=6.444 * ( 1 - 24.65% )/( (32.359 + 40.632)/ 2 )
=4.855554/36.4955
=13.30 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=44.423 - 1.68 - ( 10.384 - max(0, 6.184 - 24.464+10.384))
=32.359

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=50.008 - 2.032 - ( 7.344 - max(0, 8.551 - 29.362+7.344))
=40.632

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Diaceutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=6.688/( ( (1.711 + max(3.31, 0)) + (1.664 + max(3.521, 0)) )/ 2 )
=6.688/( ( 5.021 + 5.185 )/ 2 )
=6.688/5.103
=131.06 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.88 + 0 + 2.385) - (1.68 + 0 + 4.275)
=3.31

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.872 + 0 + 1.93) - (2.032 + 0 + 6.249)
=3.521

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Diaceutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=0.36/116.521
=0.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diaceutics EBIT Related Terms

Diaceutics EBIT Historical Data

* Premium members only.

The historical data trend for Diaceutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diaceutics EBIT Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.68 -2.37 -1.85 0.36

Diaceutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.46 -3.24 1.38 -2.98 3.34

LSE:DXRX vs VEEV, BTSG, TEM: EBIT Comparison

For the Health Information Services subindustry, Diaceutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diaceutics EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Diaceutics's EV-to-EBIT falls into.


LSE:DXRX
92GF Score
Diaceutics PLC LSE:DXRX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diaceutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of £0.36 Mil mean?
Diaceutics (LSE:DXRX) has a EBIT of £0.36 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Diaceutics.
Is Diaceutics' EBIT too high?
Diaceutics' current EBIT is £0.36 Mil. Overall, Diaceutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' EBIT compare to VEEV and BTSG?
Diaceutics' EBIT of £0.36 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Diaceutics. Diaceutics's current EBIT is £0.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (LSE:DXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is £1.91, compared to a current price of £1.45 — trading 24.1% below its estimated fair value. The current EBIT is £0.36 Mil. Diaceutics' overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Diaceutics (LSE:DXRX), the current EBIT is £0.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diaceutics (LSE:DXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued. The current stock price of £1.45 is trading 24.1% below its estimated GF Value™ of £1.91. GuruFocus considers Diaceutics to be Modestly Undervalued.

Key valuation signals for LSE:DXRX:

  • EBIT: £0.36 Mil
  • GF Value™: £1.91 vs. price of £1.45 (24.1% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the LSE:DXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diaceutics Business Description

Other Exchanges DIUXF:USA7DC:Germany
Address Dataworks at Kings Hall Health & Wellbeing Park, First Floor, Building Two, County Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
92GF Score

Get the complete analysis for LSE:DXRX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.45
Price
£1.91
GF Value